Phase 2 Study Examines Treatment Sequencing for HER2-Positive Breast Cancer

HER2-positive breast cancer is characterised by increased expression of the HER2 protein, which can encourage cancer cells to grow. HER2-targeted medicines have become an important part of treatment for this subtype, often used alongside chemotherapy.

The METIS phase 2 study examines whether chemotherapy and HER2-targeted medicines should be administered concurrently or sequentially before surgery. This treatment period is known as neoadjuvant therapy. It is used to reduce tumour size, assess how the cancer responds and help clinicians plan subsequent treatment.

The sequencing of medicines matters because treatment effectiveness, toxicity and the ability to complete therapy can differ between approaches. The publication adds to research on how to optimise pre-surgical treatment for HER2-positive disease. Its findings should be interpreted from the full paper, including its patient numbers, response outcomes and adverse-event data. A phase 2 study does not by itself establish a new universal standard of care.